

## Myeloid NGS Panel: Change in Assay/Platform

Date: July 3<sup>rd</sup>, 2024

Effective Date: August 21st, 2024

The Molecular Diagnostic Laboratory will shift from the current Myeloid NGS assay, which utilizes the Illumina TruSight panel (to be discontinued by Illumina), to the Thermo Fisher Oncomine Myeloid Assay v2. Ordering procedures for the new assay will remain unchanged (MCMP).

The Oncomine Myeloid Assay is performed on the Thermo Fisher Genexus platform, offering advantages such as a highly automated workflow and significantly reduced turnaround times (5-10 working days). This assay will enhance our gene coverage, increasing from 35 to 45 genes. Notably, the Oncomine Myeloid Assay can detect mutations in the genes *CEBPA* and *CALR*, which are not covered by the current Illumina TruSight Myeloid panel. Additionally, the new panel includes full gene or hotspot region coverage for the following genes not covered by the Illumina Myeloid Assay: *ABL1*, *ANKRD26*, *DDX41*, *HRAS*, *IKZF1*, *NF1*, *PPM1D*, *PRPF8*, *RB1*, *SH2B3*, *SMC1A*, and *SMC3*.

Genes covered on the Illumina Myeloid Panel but not on the Oncomine Myeloid Assay are: *NOTCH1* and *GATA1*.

## **Oncomine Myeloid Assay Gene List:**

Hotspot genes (28)		Full genes (17)	
ANKRD26 ABL1 BRAF CBL CSF3R DDX41 DNMT3A FLT3 (ITD + TKD) GATA2 HRAS IDH1 IDH2 JAK2 KIT	KRAS MPL MYD88 NPM1 NRAS PPM1D PTPN11 SMC1A SMC3 SETBP1 SF3B1 SRSF2 U2AF1 WT1	ASXL1 BCOR CALR CEBPA ETV6 EZH2 IKZF1 NF1 PHF6	PRPF8 RB1 RUNX1 SH2B3 STAG2 TET2 TP53 ZRSR2



With the launch of the Oncomine Myeloid Assay, we will be deactivating the Mayo NGSHM send-out.

From: Zoltan Oltvai, M.D.

Director of the Molecular Diagnostic Laboratory

UR Medicine Labs Phone: (585) 273-2229

Email: Zoltan\_Oltvai@urmc.rochester.edu

Paige Elliott

Supervisor, Molecular Diagnostic Laboratory

Phone: (585) 275-2709

Email: Paige\_Elliott@urmc.rochester.edu